News for ZSAN Stock

Zosano Pharma Files Voluntary Petition for Relief Under Chapter 11 Zosano Pharma Reports First Quarter 2022 Financial Results Zosano Pharma Provides Corporate Update Zosano Pharma Announces Reverse Stock Split Effective Today Zosano Pharma Reports Fourth Quarter and Fiscal Year 2021 Financial Results Zosano Pharma Announces Pricing of $15.4 Million Public Offering of Common Stock and Warrants Zosano Pharma Announces Proposed Public Offering of Common Stock and Warrants CORRECTION - Zosano Pharma Announces Publication of Clinical Data Demonstrating Comparable Immunogenicity of a Trivalent Influenza Vaccine Formulated on its Transdermal Microneedle System Versus an Intramuscular Injection of the Vaccine at a Higher Dose Zosano Pharma Announces Publication of Clinical Data Demonstrating Comparable Immunogenicity of a Trivalent Influenza Vaccine Formulated on its Transdermal Microneedle System Versus an Intramuscular Injection of the Vaccine at a Higher Dose Zosano Pharma Announces Changes to Board of Directors; Appoints Cross Functional Business Executive Elaine M. Yang Zosano Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Zosano Pharma Announces the Successful Formulation of a COVID-19 Vaccine Candidate on its Microneedle Patch System Zosano Pharma Reports Third Quarter 2021 Financial Results Zosano Pharma Granted Type C Meeting with FDA Regarding NDA Resubmission for M207 Following Preliminary Top-Line Pharmacokinetic Study Results Zosano Pharma to Present at the H.C. Wainwright Virtual Global Investment Conference Zosano Pharma Reports Second Quarter 2021 Financial Results Zosano Pharma Announces Issuance of U.S. Patent for Method of Rapidly Achieving Therapeutic Levels with M207 for the Acute Treatment of Migraine Zosano Pharma Announces Publication of Clinical Data Regarding the Long-term use of Qtrypta™ for the Treatment of Acute Migraine in The Journal of Headache and Pain Zosano Appoints Industry Veteran, Kathy McGee, to its Board of Directors Zosano Pharma Reports First Quarter 2021 Financial Results Zosano Pharma Confirms Plan to Move Forward with Pharmacokinetic Study Following Protocol Review by FDA Zosano Pharma Reports Fourth Quarter and Fiscal Year 2020 Financial Results Zosano Pharma to Present at the H.C. Wainwright Global Life Sciences Conference Zosano Pharma Confirms NDA Resubmission Strategy Following Type A Meeting Minutes from FDA Zosano Pharma Presents Early-Onset of Action Data for Qtrypta™ in Acute Treatment of Migraines Zosano Pharma Announces NDA Resubmission Plans Following Type A Meeting with FDA Zosano Pharma Requests Type A Meeting with the FDA to Review Resubmission Plans for Qtrypta™ New Drug Application Zosano Pharma to Present at the H.C. Wainwright Virtual BioConnect Conference Zosano Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Zosano Pharma Reports Third Quarter 2020 Financial Results Zosano Pharma Receives Complete Response Letter from FDA for Qtrypta™ Zosano Pharma to Present at the H.C. Wainwright Annual Global Investment Conference Zosano Pharma Announces Proposed Public Offering of Common Stock Zosano Pharma Announces Agreement to Collaborate with Mitsubishi Tanabe Pharma Corporation Zosano Pharma Announces Partnership Agreement with EVERSANA to Support the Launch and Commercialization of Qtrypta™ Zosano Pharma Reports Second Quarter 2020 Financial Results and Provides Corporate Update Zosano Pharma to Present at the BTIG Biotechnology Conference 2020 Zosano Pharma Announces Change to a Virtual Meeting Format for 2020 Annual Meeting of Stockholders Zosano Pharma Announces the Appointment of Christine Matthews as Chief Financial Officer Zosano Pharma to showcase new post-hoc analyses of Qtrypta’s (M207) clinical trial data comparing key efficacy results from the pivotal study and the open-label long term safety study on the 2020 American Headache Society’s Virtual Annual Scientific Meetin Zosano Pharma Reports First Quarter 2020 Financial Results and Provides Corporate Update